Prospects for mucosal vaccine: shutting the door on SARS-CoV-2

82Citations
Citations of this article
198Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The sudden emergence of a highly transmissible and pathogenic coronavirus SARS-CoV-2 in December 2019 from China and its rapid global spread has posed an international health emergency. The rapid development of an effective vaccine is imperative to control the spread of SARS-CoV-2. A number of concurrent efforts to find an effective therapeutic agent or vaccine for COVID-19 (coronavirus disease 2019) are being undertaken globally. Oral and nasal mucosal surfaces serve as the primary portal of entry for pathogens like coronaviruses in the human body. As evidenced by studies on similar coronaviruses (SARS-CoV and MERS-CoV), mucosal vaccination can provide a safe and effective means for the induction of long-lasting systemic and mucosal immunity to confer protection against SARS-CoV-2. This article summarizes the approaches to an effective mucosal vaccine formulation which can be a rewarding approach to combat the unprecedented threat posed by this emerging global pandemic.

Cite

CITATION STYLE

APA

Mudgal, R., Nehul, S., & Tomar, S. (2020). Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Human Vaccines and Immunotherapeutics, 16(12), 2921–2931. https://doi.org/10.1080/21645515.2020.1805992

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free